Characterization of drug-drug interactions in patients whose substance intake was objectively identified by detection in urine

References

• Bykov K, Gagne JJ. Generating evidence of clinical outcomes of drug-drug interactions. Drug Saf. 2017;40:101–103.
   PubMed Web of Science ®Google Scholar
• Cai R, Liu M, Hu Y, et al. Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports. Artif Intell Med. 2017;76:7–15.
   PubMed Web of Science ®Google Scholar
• Liu R, AbdulHameed MDM, Kumar K, et al. Data-driven prediction of adverse drug reactions induced by drug-drug interactions. BMC Pharmacol Toxicol. 2017 Jun 8;18(1):44.
   PubMedGoogle Scholar
• Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266–272.
   PubMed Web of Science ®Google Scholar
• Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE prevention study group. JAMA. 1995 Jul 5;274(1):29–34.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995 Oct 9;155(18):1949–1956.
   PubMed Web of Science ®Google Scholar
• Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA. 1997 Jan 22–29;277(4):307–311.
   PubMed Web of Science ®Google Scholar
• IMS Health. Avoidable costs in U.S. healthcare. The $200 billion opportunity from using medicines more responsibly. Parsippany (NJ): IMS Institute for Healthcare Informatics; 2013.
   Google Scholar
• Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):192–199.
   PubMedGoogle Scholar
• Day RO, Snowden L, McLachlan AJ. Life-threatening drug interactions: what the physician needs to know. Inter Med J. 2017 May;47(5):501–512.
   Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
   PubMed Web of Science ®Google Scholar
• Hanlon JT, Perera S, Newman AB, et al. Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults. J Clin Pharm Ther. 2017 Apr;42(2):228–233.
   PubMed Web of Science ®Google Scholar
• Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish prescribed drug register. Drug Saf. 2007;30(10):911–918.
   PubMed Web of Science ®Google Scholar
• Fried TR, O’Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014 Dec;62(12):2261–2272.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Health, United States, 2016: with chartbook on long-term trends in health. Hyattsville (MD): National Center for Health Statistics; 2017. (DHHS publication; no. 2017-1232).
   Google Scholar
• Makiani MJ, Nasiripour S, Hosseini M, et al. Drug-drug interactions: the importance of medication reconciliation. J Res Pharm Pract. 2017 Jan-Mar;6(1):61–62.
   PubMed Web of Science ®Google Scholar
• The Joint Commission: National Patient Safety Goals Effective January 2018: Ambulatory Health Care Accreditation Program [Internet]. Oakbrook Terrace (IL): The Joint Commission; c2018. National Patient Safety Goals®; 2018 Jan [cited 2018 Jul 3]; [11 pages]. Available from: https://www.jointcommission.org/assets/1/6/NPSG_Chapter_AHC_Jan2018.pdf
   Google Scholar
• Almanasreh E, Moles R, Chen TF. The medication reconciliation process and classification of discrepancies: a systematic review. Br J Clin Pharmacol. 2016 Sep;82(3):645–658.
   PubMed Web of Science ®Google Scholar
• Marien S, Krug B, Spinewine A. Electronic tools to support medication reconciliation: a systematic review. J Am Med Inform Assoc. 2017 Jan;24(1):227–240.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Labhsetwar SA, Amy Puenpatom R, et al. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract. 2012 Jan;12(1):45–56.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Labhsetwar SA, Puenpatom RA, et al. Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Pract. 2012 Jan;12(1):33–44.
   PubMed Web of Science ®Google Scholar
• Summers KH, Puenpatom RA, Rajan N, et al. Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ. 2011;14(4):390–396.
   PubMedGoogle Scholar
• Giummarra MJ, Gibson SJ, Allen AR, et al. Polypharmacy and chronic pain: harm exposure is not all about the opioids. Pain Med. 2015;16:472–479.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Labhsetwar SA, Puenpatom RA, et al. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract. 2011 May-Jun;11(3):230–239.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr., Labhsetwar SA, Puenpatom RA, et al. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract. 2011 Jul-Aug;11(4):325–336.
   PubMed Web of Science ®Google Scholar
• Doan J, Zakrzewski-Jakubiak H, Roy J, et al. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013 Mar;47(3):324–332.
   PubMed Web of Science ®Google Scholar
• Pedros C, Formiga F, Corbella X, et al. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Eur J Clin Pharmacol. 2016 Feb;72(2):219–226.
   PubMed Web of Science ®Google Scholar
• Santos TRA, Silveira EA, Pereira LV, et al. Potential drug-drug interactions in older adults: a population-based study. Geriatr Gerontol Int. 2017;17:2336–2346.
   PubMed Web of Science ®Google Scholar
• Laatikainen O, Sneck S, Bloigu R, et al. Hospitalizations due to adverse drug events in the elderly-a retrospective register study. Front Pharmacol. 2016;7:358.
   PubMed Web of Science ®Google Scholar
• Ryan TP, Morrison RD, Sutherland JJ, et al. Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring. PLoS ONE. 2017;12(9):e0185471.
   PubMed Web of Science ®Google Scholar